Cullin 3 Promotes Proteasomal Degradation of the Topoisomerase I-DNA Covalent Complex
Overview
Affiliations
DNA topoisomerase I (TOP1)-DNA covalent complexes are the initial lesions produced by antitumor camptothecins (CPTs). The TOP1-directed drugs stimulate degradation of TOP1 via the ubiquitin-proteasome pathway. We found that proteasome inhibition prevents degradation of DNA-bound TOP1 and sustains high levels of covalent complexes, thus enhancing CPT-induced cell death. Consistent with this, increased degradation of TOP1-DNA covalent complexes was seen in acquired CPT-resistant cells. We found that the resistant cells showed elevated expressions of Cul3, a member of the cullin family of E3 ubiquitin ligases. The reduction in Cul3 expression by small interfering RNA decreased degradation of TOP1-DNA covalent complexes. Conversely, Cul3 overexpression by stable transfection promoted covalent complex degradation and reduced CPT-induced cell death without affecting basal TOP1 expression levels. These results indicate that Cul3, by promoting proteasomal degradation of TOP1-DNA covalent complexes, becomes an important regulator for cellular CPT sensitivity.
Autophagy as a way to remove DNA lesions.
Lei Y, Klionsky D Autophagy. 2024; 21(3):497-499.
PMID: 39635883 PMC: 11849940. DOI: 10.1080/15548627.2024.2434784.
From the TOP: Formation, recognition and resolution of topoisomerase DNA protein crosslinks.
Wojtaszek J, Williams R DNA Repair (Amst). 2024; 142:103751.
PMID: 39180935 PMC: 11404304. DOI: 10.1016/j.dnarep.2024.103751.
Gu S, Lin C, Li Y, Wei Z, Cao B, Shen Z Eur J Med Res. 2023; 28(1):326.
PMID: 37689760 PMC: 10492332. DOI: 10.1186/s40001-023-01289-y.
NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors.
Meroni A, Grosser J, Agashe S, Ramakrishnan N, Jackson J, Verma P Sci Adv. 2022; 8(49):eabq0648.
PMID: 36490343 PMC: 9733930. DOI: 10.1126/sciadv.abq0648.
Targeting DNA-Protein Crosslinks Post-Translational Modifications.
Leng X, Duxin J Front Mol Biosci. 2022; 9:944775.
PMID: 35860355 PMC: 9289515. DOI: 10.3389/fmolb.2022.944775.